Table 3.

Resistance-Associated Substitution Distribution Among PREVAIL Participants With Virologic Relapse

Study ID	Genotype	Regimen	Cirrhosis	Average Daily Adherence	Treatment Outcome	Baseline			Treatment Week 4			End of Treatment			Week 4 Posttreatment			Week 12 Posttreatment			Week 24 Posttreatment
						NS3/4A	NS5A	NS5B	NS3/4A	NS5A	NS5B	NS3/4A	NS5A	NS5B	NS3/4A	NS5A	NS5B	NS3/4A	NS5A	NS5B	NS3/4A	NS5A	NS5B
AL1021	1b	SOF/RBV	No	78.73	Treatment failure	S122G			S122G			S122G						S122G			S122G
AL1024	1a	SOF/RBV/ PEG	No	-	Treatment failure	R155R/K			R155R/K						R155R/K			R155R/K
AL1035	1a	SOF/LDV	Yes	43	Treatment failure	Q80K									Q80K						Q80K
AL1046	1a	SOF/LDV	No	31.4	Treatment failure		H58P									L31M/V, H58P			L31M/V, H58P			L31M, H58P
AL2009	1a	SOF/RBV	No	45.17	Treatment failure	Q80K						Q80K		L159L/F	Q80K
AL2020	1a	SOF/LDV	No	82.17	Treatment failure											Q30H, Y93H			Q30H, Y93H			Q30H, Y93H
AL1080	1a	SOF/LDV	No	38	Treatment failure	Q80K
AL1019	1a	SOF/RBV	Yes	53.5	Late relapse
AL1020	1a	SOF/RBV	No	88.77	Reinfection			G307R
AL1075	1a	SOF/LDV	Yes	58.42	Reinfection	Q80K/L
AL2019	1a	SIM/SOF	Yes	57.09	Reinfection	Q80K

Abbreviations: ID, identification; PEG, pegylated; SIM, simeprevir; SOF/LDV, sofosbuvir/ledipasvir; SOF/RBV, sofosbuvir, ribavirin.